COVID-19：富士フイルム､VLP Therapeuticsと契約：ワクチン製造受託（動画）：
COVID-19: FUJIFILM contract with VLP Therapeutics: Vaccine manufacturing:
COVID-19：Fujifilm与VLP Therapeutics签订合同：疫苗的合同生产
-ドラッグ・デリバリー・システム技術を用いた製造受託ー
VLP Therapeutics社：
日本でのワクチン開発に向け、国立研究開発法人 AMED・公募ワクチン開発（2次公募）に応募しました。
2020年8月、VLP Therapeuticsの次世代COVID-19ワクチンの開発が、研究開発課題として採択されました。
次世代ワクチンの開発：
- 国立国際医療研究センター、
- 医薬基盤・健康・栄養研究所、
- 大分大学および大阪市立大学と
共同で、次世代COVID-19ワクチンの臨床開発を行う予定です。
富士フイルム [日本]
https://www.fujifilm.com/jp/ja/news/list/5493
Fujifilm Concludes a Manufacturing Contract Agreement with VLP Therapeutics,
for a COVID-19 Vaccine Formulation
TOKYO, October 1, 2020—
FUJIFILM Corporation
has announced the conclusion of a manufacturing contract agreement with biotechnology company VLP Therapeutics Japan LLC regarding a COVID-19 vaccine formulation developed by VLP Therapeutics.
VLP Therapeutics’ COVID-19 vaccine
is a self-amplifying (replicon) RNA*1vaccine that uses a formulation (lipid nanoparticle)*2, which is a type of Drug Delivery System (DDS) technology*3.
Fujifilm
will utilize its manufacturing facilities and infrastructure for lipid nanoparticle to handle operations relating to VLP Therapeutics’ COVID-19 vaccine formulations, from process development to manufacturing for clinical trials.
VLP Therapeutics is the Japanese subsidiary of VLP Therapeutics, LLC, a U.S. biotechnology company engaged in the development of next-generation COVID-19 vaccines, aiming to prevent infections for which no effective treatment methods exist.
Research
is currently under way at VLP Therapeutics LLC to produce next-generation COVID-19 vaccines that can, by using replicons, demonstrate a high amount of efficacy even with inoculation in small amounts, reduce the risk of adverse reactions, and cope with some genetic mutation.